.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Baxter
Fish and Richardson
Citi
Dow
Deloitte
US Department of Justice
Colorcon
Healthtrust
Argus Health

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,010,718

« Back to Dashboard

Which drugs does patent 6,010,718 protect, and when does it expire?


Patent 6,010,718 protects BIAXIN XL and is included in one NDA. There has been one Paragraph IV challenge on Biaxin XL.

This patent has fifty-nine patent family members in twenty-nine countries.

Summary for Patent: 6,010,718

Title: Extended release formulations of erythromycin derivatives
Abstract:Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower C.sub.max in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
Inventor(s): Al-Razzak; Laman (Highland Park, IL), Crampton; Sheri L. (Gurnee, IL), Gustavson; Linda E. (Evanston, IL), Hui; Ho-Wah (Libertyville, IL), Milman; Nelly (Skokie, IL), Semla; Susan J. (Evanston, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:08/838,900
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie
BIAXIN XL
clarithromycin
TABLET, EXTENDED RELEASE;ORAL050775-001Mar 3, 2000DISCNYesNo► Subscribe► SubscribeY TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,010,718

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,551,616 Extended release formulations of erythromycin derivatives► Subscribe
6,872,407 Extended release formulations of erythromycin derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,010,718

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia288127► Subscribe
Slovakia288109► Subscribe
Slovakia138099► Subscribe
Slovenia0973527► Subscribe
Saudi Arabia920► Subscribe
Portugal973527► Subscribe
Poland402949► Subscribe
Poland354783► Subscribe
Poland336142► Subscribe
New Zealand596215► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
US Department of Justice
AstraZeneca
Harvard Business School
Moodys
Chubb
Queensland Health
Medtronic
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot